Pritelivir information

Pritelivir
Names
	Systematic IUPAC name N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide
Identifiers
CAS Number	348086-71-5 ;
3D model (JSmol)	Interactive image;
ChemSpider	430613;
KEGG	D12811;
PubChem CID	491941;
UNII	07HQ1TJ4JE ;
CompTox Dashboard (EPA)	DTXSID70188344 ;
	InChI InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25) Key: IVZKZONQVYTCKC-UHFFFAOYSA-N; InChI=1/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25) Key: IVZKZONQVYTCKC-UHFFFAOYAL;
	SMILES Cc1c(sc(n1)N(C)C(=O)Cc2ccc(cc2)c3ccccn3)S(=O)(=O)N;
Properties
Chemical formula	C18H18N4O3S2
Molar mass	402.49 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Pritelivir is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. Pritelivir is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG.

US FDA granted Fast Track Designation for pritelivir in 2017.
US FDA granted Breakthrough Therapy Designation for pritelivir in 2020.

Pritelivir is also known as AIC316 or BAY 57-1293.

Pritelivir information

and 4 Related for: Pritelivir information

Pritelivir

Herpes simplex research

Anna Wald

Lawrence Corey